UNSPSC 51182707: Metformin/rosiglitazone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182707 Metformin/rosiglitazone is a Commodity code whose title does not align with recent state and local procurement activity posted under it. The two recent opportunities on record involve naloxone and drug deactivation systems (Seminole County, Florida) and a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program (Texas Health and Human Services Commission), neither of which relates to metformin or rosiglitazone diabetes medications. The code shows minimal relevant recent activity and appears to be tagged inconsistently with the work actually being procured.

The issuing bodies pursuing opportunities under this code include county health departments (Seminole County) and state health and human services agencies (Texas HHS Commission). Geographic activity is concentrated in Florida and Texas. The Seminole County procurement is an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the bid response deadline was July 26, 2023. The Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription fulfillment models for self-insured employer and state agency plans, with no formal evaluation timeline or award value specified at that exploratory stage. Neither opportunity demonstrates active procurement demand for the diabetes medications the code nominally covers, suggesting this code is either dormant for its intended scope or routinely mistagged in state and local posting systems.